Emergent BioSolutions Return on Equity

Emergent BioSolutions (0IGA.L) currently reports a ROE of -53.78%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Emergent BioSolutions's ROE history and peer comparisons.

Emergent BioSolutions's ROE of -53.78% is higher than the Healthcare sector average of -75.84%. That is roughly 29.1% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Emergent BioSolutions's current -53.78% should be judged against Healthcare norms (sector average: -75.84%) and against 0IGA.L's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -53.78%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Emergent BioSolutions, and consider following 0IGA.L for alerts when major investors trade the stock.

Emergent BioSolutions is classified in the Healthcare sector. On ROE, it currently shows -53.78% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0IGA.L with unrelated industries.